🇺🇸 Dexamethasone Sodium Phosphate Injection, USP in United States

202 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Injection Site Pain — 44 reports (21.78%)
  2. Product Use In Unapproved Indication — 32 reports (15.84%)
  3. Intentional Product Use Issue — 22 reports (10.89%)
  4. Off Label Use — 18 reports (8.91%)
  5. Pneumocystis Jirovecii Pneumonia — 18 reports (8.91%)
  6. Drug Ineffective — 17 reports (8.42%)
  7. Pain — 15 reports (7.43%)
  8. Arthralgia — 13 reports (6.44%)
  9. Dizziness — 12 reports (5.94%)
  10. Feeling Abnormal — 11 reports (5.45%)

Source database →

Dexamethasone Sodium Phosphate Injection, USP in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Dexamethasone Sodium Phosphate Injection, USP approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Dexamethasone Sodium Phosphate Injection, USP in United States?

Mercator MedSystems, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.